The sales department of the pharmaceutical company adjusts the establishment of the organization.
Release time:
2021-03-22
News from our newspaper Reporters learned from the pharmaceutical company's marketing work meeting held on 3# April 9 that the pharmaceutical company's sales department has adjusted its marketing plan and organization settings.
In this institutional adjustment, the sales department has set up "two departments and two centers": the first business department is responsible for the sales business of the whole country (except Zhejiang terminal) and the bidding work; The second business department is responsible for the sales business of Zhejiang terminal (including self-operated and non-staff), as well as logistics, accounting and other work. The market center is responsible for academic promotion, expert maintenance and brand building; the Cargo Control Center is responsible for the maintenance of the pharmaceutical company's product market price system and anti-tampering management.
In recent years, with the promotion and implementation of national and provincial centralized procurement, the sales volume of major customers of individual products has obviously shrunk. At the same time, due to the intersection of the commission system and the business of major customers, communication and coordination problems have arisen in the development of various sectors. The commission system has been initially constructed through the infrastructure construction in 2020 , but there are deficiencies in subjective initiative, business skills, etc, the team needs to be further optimized and deepened; the team is not self-driven and lacks a sense of operational risk. To this end, in 2021 , the sales department adjusted its marketing model in a timely manner to enhance its market expansion capability based on the idea of "preserving base volume, adding new volume and activating stock. In terms of agency, the sales department adopts the model of "3 6 X " provinces and regions. Guangdong, Zhejiang and Shanghai 3 provinces and regions are responsible for the selected personnel of the pharmaceutical company to ensure the basic amount. Hunan, Henan, Shandong, Anhui, Fujian and Hubei 6 provinces and autonomous regions will have new employees as provincial managers to strive for new increments. The remaining provinces and autonomous regions will determine their provincial managers through bidding. The sales department also merged Zhejiang terminal offices according to the market business situation, setting up a total of 4 offices to further strengthen management. Jiang Xiaomeng, chairman of the group company and chairman of the pharmaceutical company, said that the purpose of the organizational reset, sales policy and team adjustment is to further promote the new development of pharmaceutical sales and enhance the management level of the sales team. He demanded that the sales staff should strengthen their own ability and learn new knowledge; the sales department should do a good job in preventing goods from fleeing and listing at low prices with a zero tolerance attitude; and further strengthen the communication between departments at all levels to better serve sales.
(ReporterNi Yingzhen)
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page